Akeso logs Phase III success in second tumour type for ivonescimab
Summit Therapeutics’ $500m upfront bet on Akeso’s PD-1 x VEGF bispecific, ivonescimab, is looking increasingly well placed, with the latter…
Oncology
-
-
Surveillance and vaccine could protect against higher cancer risk from Lynch syndrome
In addition to cancer risk factors such as ageing, environmental risk factors, and lifestyle risk factors, family history of cancer…
-
Orum to begin Phase I trial of ORM-1153 after FDA clearance
The US Food and Drug Administration (FDA) has approved Orum Therapeutics' investigational new drug (IND) application for ORM-1153, a new…
-
AstraZeneca trips in PD-1 bispecific market after Phase III NSCLC failure
On 17 August, AstraZeneca discontinued the eVOLVE-Lung02 Phase III trial of volrustomig in combination with chemotherapy in first-line metastatic non-small…
-
AstraZeneca axes NSCLC trial after bispecific deemed unlikely to best Keytruda
AstraZeneca has ended a Phase III trial of its bispecific volrustomig pitted against MSD’s blockbuster Keytruda (pembrolizumab) in non-small cell…
-
UK Prime Minister to meet with brain cancer patient after research appeal
The UK's Prime Minister, Andy Burnham, has agreed to meet with a Team GB swimmer who suffers from brain cancer…
-
ASCO26: AI innovations show promise in reducing the oncology RWD burden
Artificial intelligence (AI) was a hot topic on the agenda at the American Society of Clinical Oncology (ASCO) meeting 2026,…
-
China’s rapid rise in drug development casts a long shadow over US oncology
2026 marks a clear turning point for China’s position in the global clinical trials arena, particularly in oncology. At this…
-
Summit debuts longer-term ivonescimab data as it awaits FDA NSCLC decision
Summit Therapeutics has released more Phase III trial data for ivonescimab in non-small cell lung cancer (NSCLC) as it awaits…
-
Nuvation Bio to advance glioma drug to Phase III trial after positive three-year data
Nuvation Bio’s glioma drug has touted a 36-month progression-free survival (PFS) rate of 79% with nearly 40 months of follow-up, with its advancement to…
